+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study



Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study



Journal of the National Medical Association 86(1): 46-52



We undertook a prospective, randomized, non-blinded pilot study to determine whether infants with respiratory distress syndrome (RDS) who were treated with protein-containing bovine surfactant (Survanta, Ross/Abbott Laboratories, Columbus, Ohio) had earlier and larger responses in gas exchange when compared with similar infants treated with a synthetic surfactant (Exosurf, Burroughs Wellcome, Research Triangle Park, North Carolina). Forty-one infants weighing between 600 g and 1750 g at birth with RDS of sufficient severity to require assisted ventilation with an FiO2 > 0.39 were enrolled in the study and treated with surfactant from 1 to 8 hours after birth. Infants were randomly selected to receive treatment with either Exosurf or Survanta. Despite randomization, the Survanta group was overrepresented with factors associated with greater severity of RDS (lower birthweight, more males, and fewer African Americans). No statistically significant difference was found in the primary outcome measure (arterial/alveolar PaO2 > 0.3 at 24 hours) by univariate or multivariate analysis. The percentage of responders in the Survanta-treated group was significantly increased 24 hours after treatment in two of four secondary measures of oxygenation when analyzed by univariate tests using one-tailed P values. Based on these results, we anticipate that acute outcomes after Survanta or Exosurf will approximate those found in this trial and that differences in measures of oxygenation between treatment groups will approximate 30% to 50% 24 hours after initial treatment.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 068675182

Download citation: RISBibTeXText

PMID: 8151722


Related references

Modified bovine surfactant versus a protein-free surfactant in the treatment of respiratory distress syndrome in preterm infants A pilot study. Journal of the National Medical Association 86(1): 46-52, 1994

Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Ross Collaborative Surfactant Prevention Study Group. Pediatrics 85(6): 1092-1102, 1990

Ductal flow patterns in preterm infants with respiratory distress syndrome rds administered artificial surfactant as survanta. Pediatric Research 27(4 Part 2): 197A, 1990

Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2015(5): Cd000144, 2015

Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 8: Cd000144, 2015

Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Archives of Disease in Childhood. Fetal and Neonatal Edition 102(1): F17-F23, 2017

Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with survanta, a modified bovine surfactant. Pediatrics 87(4): 505-510, 1991

Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. The Surfactant-TA Study Group. Pediatrics 86(5): 753-764, 1990

Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: a multicenter controlled clinical trial. Pediatric Pulmonology 14(1): 4-9, 1992

A multicenter randomized trial comparing synthetic surfactant to modified bovine surfactant extract in the treatment of neonatal Respiratory Distress Syndrome. Pediatric Research 35(4 Part 2): 259A, 1994

Surfactant treatment before first breath for respiratory distress syndrome in preterm lambs: comparison of a peptide-containing synthetic lung surfactant with porcine-derived surfactant. Drug Design Development and Therapy 7: 905-916, 2013

Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009(4): Cd006180, 2009

Nebulized surfactant for treatment of respiratory distress syndrome A pilot study in preterm babies. Biology of the Neonate 74(Suppl. 1): 51, 1998

Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 88(1): 84-89, 1991

One-year follow-up of 273 infants with birth weights of 700 to 1100 grams after prophylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo. American Exosurf Neonatal Study Group I. Journal of Pediatrics 126(5 Pt 2): S20-S25, 1995